Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling.

Abstract:

BACKGROUND:Insulin resistance (IR) is a well-known risk factor for cardiovascular complications. This study aimed to investigate the effect of a dietary model of IR in mice on cardiac remodeling, cardiac β-arrestin2 signaling, and the protective effects of carvedilol as a β-arrestin-biased agonist. METHODS AND RESULTS:Insulin resistance was induced by feeding mice high-fructose/high-fat diet (HFrHFD) for 16 weeks. Carvedilol was adiministered for 4 weeks starting at week 13. At the end of the experiment, body weight, heart weight, left and right ventricular thickness, visceral fat weight, fasting blood glucose (FBG), serum insulin, IR index, and serum endothelin-1 were measured. In addition, cardiac tissue samples were histopathologically examined. Also, cardiac levels of cardiotrophin-1, β-arrestin2, phosphatidylinositol 4,5 bisphosphate (PIP2), diacylglycerol (DAG), and phosphoserine 473 Akt (pS473 Akt) were measured. Results showed significant increases in the FBG, serum insulin, IR index, serum endothelin-1, cardiac DAG, cardiac fibrosis, and degenerated cardiac myofibrils in HFrHFD-fed mice associated with a significant reduction in cardiac levels of cardiotrophin-1, β-arrestin2, PIP2, and pS473 Akt. On the other hand, carvedilol significantly reduced the heart weight, FBG, serum insulin, IR index, serum endothelin-1, cardiac DAG, left ventricular thickness, right ventricular fibrosis, and degeneration of cardiac myofibrils. In addition, carvedilol significantly increased cardiac levels of cardiotrophin-1, β-arrestin2, PIP2, and pS473 Akt. CONCLUSION:Carvedilol enhances cardiac β-arrestin2 signaling and reduces cardiac remodeling in HFrHFD-fed mice.

authors

Ibrahim WS,Ibrahim IAAE,Mahmoud MF,Mahmoud AAA

doi

10.1177/1074248420905683

subject

Has Abstract

pub_date

2020-07-01 00:00:00

pages

354-363

issue

4

eissn

1074-2484

issn

1940-4034

journal_volume

25

pub_type

杂志文章
  • Harnessing the Therapeutic Potential of MicroRNAs for Cardiovascular Disease.

    abstract::Cardiovascular diseases are one of the most common causes of death in humans and are responsible for billions of dollars in health care expenditures. As the molecular basis of cardiac diseases continues to be explored, there remains the hope for identification of more effective therapeutics. MicroRNAs (miRNAs) are rec...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248414552902

    authors: Calway T,Kim GH

    更新日期:2015-03-01 00:00:00

  • Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis.

    abstract:BACKGROUND:Published data indicated that combination use of clopidogrel and proton pump inhibitors (PPIs) may increase the incidence of major adverse cardiovascular events (MACEs). This has been a highly controversial topic for years. DESIGN:The present study was performed to evaluate whether combination therapy of cl...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248416663647

    authors: Niu Q,Wang Z,Zhang Y,Wang J,Zhang P,Wang C,Yin X,Hou Y

    更新日期:2017-03-01 00:00:00

  • Effects of pre- and postconditioning on arrhythmogenesis in the in vivo rat model.

    abstract::The antiarrhythmic potential of postconditioning in in vivo models remains poorly defined. We compared the effects of pre- and postconditioning on ventricular arrhythmogenesis against controls with and without reperfusion. Wistar rats (n = 40, 269 ± 3 g) subjected to ischemia (30 minutes)--reperfusion (24 hours) were ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248413482183

    authors: Kolettis TM,Vilaeti AD,Tsalikakis DG,Zoga A,Valenti M,Tzallas AT,Papalois A,Iliodromitis EK

    更新日期:2013-07-01 00:00:00

  • Age-Related Considerations in Cardio-Oncology.

    abstract::Cardio-Oncology has blossomed as a new field in cardiovascular medicine, in large part due to new therapies, which may have cardiovascular sequelae. Despite this, anthracyclines still serve as cornerstone therapy for most pediatric cancers, several solid tumors and hematological malignancies. Cardiotoxicity is the mai...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248420968689

    authors: Screever EM,Meijers WC,Moslehi JJ

    更新日期:2021-03-01 00:00:00

  • New frontiers in myocardial protection: a systems biology approach.

    abstract::Myocardial ischemic injury and cardioprotection are characterized by a cascade of molecular changes, which includes gene expression, protein expression, protein localization, interactions, and posttranslational modifications (PTMs). A systems biology approach allows the study of these genes and proteins on a large sca...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248411415855

    authors: Lotz C,Liem D,Ping P

    更新日期:2011-09-01 00:00:00

  • Novel oral anticoagulants in cardiovascular disease.

    abstract::Nonvalvular atrial fibrillation (AF) confers an increased risk of thromboembolism, with a 5-fold higher risk of ischemic stroke. Oral anticoagulation (OAC) has shown to be highly effective in preventing stroke and mortality compared to placebo and is also used in patients without AF for both treatment and prophylaxis ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248413501392

    authors: Gallego P,Roldán V,Lip GY

    更新日期:2014-01-01 00:00:00

  • Persistence of Atrial Fibrillation After Its Induction-Importance of the Duration and Dispersion of Atrial Refractoriness and Electrical Remodeling.

    abstract::BACKGROUND: The electrophysiologic mechanisms of the persistence of atrial fibrillation (AF) after its initiation are not well understood. Therefore, the electrophysiologic characteristics of the right atrium were evaluated in an acute, pacing-induced model of AF in the pig in order to identify parameters associated w...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849900400206

    authors: Rahme MM,Cotter B,Leistad E,Subudhayangkul S,Wadhwa M,Ungab G,Feld GK

    更新日期:1999-04-01 00:00:00

  • Effects of rotigaptide, a gap junction modifier, on defibrillation energy and resuscitation from cardiac arrest in rabbits.

    abstract::The gap junction modifier Rotigaptide (ZP123), which promotes cellular coupling, was hypothesized to decrease defibrillation thresholds during prolonged ventricular fibrillation (VF). Thirty-two New Zealand white rabbits were randomized to receive saline (control, n = 16) or Rotigaptide (n = 16). Following 4 min of un...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248406298021

    authors: Zhong JQ,Laurent G,So PP,Hu X,Hennan JK,Dorian P

    更新日期:2007-03-01 00:00:00

  • Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease.

    abstract::The results of numerous long-term, randomized trials show that statins significantly decrease the risks of myocardial infarction, stroke, and vascular death as well as total mortality. The benefits of statins on cardiovascular disease in patients who are not experiencing acute coronary syndromes generally become appar...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/107424840400900i109

    authors: Novela C,Hennekens CH

    更新日期:2004-03-01 00:00:00

  • Evaluation of TReatment With Angiotensin Converting Enzyme Inhibitors and the Risk of Lung Cancer: ERACER-An Observational Cohort Study.

    abstract:INTRODUCTION:Angiotensin converting enzyme inhibitors (ACEIs) are widely prescribed medications. A recent British study reported a 14% increased risk of lung cancer with ACEI versus angiotensin receptor blocker (ARB) prescriptions, and risk increased with longer use. We sought to validate this observation. METHODS:We ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248420987054

    authors: Anderson JL,Knowlton KU,Muhlestein JB,Bair TL,Le VT,Horne BD

    更新日期:2021-01-29 00:00:00

  • Curcumin attenuates cardiopulmonary bypass-induced lung oxidative damage in rats.

    abstract:OBJECTIVE:Acute lung injury is a common complication after cardiopulmonary bypass (CPB). Oxidative damage greatly impacts CPB-induced lung ischemic pathogenesis and may represent a target for treatment. We aimed to investigate whether curcumin upregulates heme oxygenase 1 (HO-1) expression and ameliorates lung injury i...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248412442002

    authors: Liu K,Chen HL,Huang H,Jing H,Dong GH,Wu HW,You QS

    更新日期:2012-12-01 00:00:00

  • CMX-2043 Efficacy in a Rat Model of Cardiac Ischemia-Reperfusion Injury.

    abstract::α-Lipoic acid (LA) has been shown to offer protection against ischemia-reperfusion injury (IRI) in multiple organ systems. N-[(R)-1,2-dithiolane-3-pentanoyl]-L-glutamyl-L-alanine (CMX-2043), a novel analogue of LA, was studied as part of a preclinical development program intended to identify safe and efficacious drug ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248416640118

    authors: Baguisi A,Casale RA,Kates SA,Lader AS,Stewart K,Beeuwkes R 3rd

    更新日期:2016-11-01 00:00:00

  • Evolving perspectives on clopidogrel in the treatment of ischemic stroke.

    abstract::Antiplatelet therapy is indicated for the treatment of ischemic stroke or transient ischemic attack (TIA). Aspirin reduces subsequent occlusive vascular events, including recurrent stroke, by about 25%. In such patients, clopidogrel has been evaluated in an effort to further reduce risk. In the Management of Atherothr...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248406296862

    authors: Gorelick P,Sechenova O,Hennekens CH

    更新日期:2006-12-01 00:00:00

  • Increasing doses of simvastatin versus combined ezetimibe/simvastatin: effect on circulating endothelial progenitor cells.

    abstract:BACKGROUND:Patients with coronary artery disease (CAD) should be treated with statins to attain very low cholesterol levels, in order to reduce cardiovascular adverse events. More than 70% of these patients do not reach the appropriate cholesterol goal despite moderate statin doses. However, it is not known whether the...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1074248413489771

    authors: Pesaro AE,Serrano CV Jr,Katz M,Marti L,Fernandes JL,Parra PR,Campos AH

    更新日期:2013-09-01 00:00:00

  • Local delivery of a hydrophobic heparin reduces neointimal hyperplasia after balloon injury in rat carotid but not pig coronary arteries.

    abstract:BACKGROUND:Intimal hyperplasia following percutaneous interventional vascular procedures is a major cause of restenosis. Although heparin inhibits intimal hyperplasia, it has not proven clinically useful in part due to an inadequate duration of intramural drug residence. This study was designed to evaluate the efficacy...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840100600407

    authors: Sasseen BM,Gray BD,Gal D,Lorinc R,Carpenter DC,Klugherz BD,Wilensky RL

    更新日期:2001-10-01 00:00:00

  • Chronic treatment with qiliqiangxin ameliorates aortic endothelial cell dysfunction in diabetic rats.

    abstract::Qiliqiangxin (QL), a traditional Chinese medicine, has been shown to be beneficial for chronic heart failure. However, whether QL can also improve endothelial cell function in diabetic rats remains unknown. Here, we investigated the effect of QL treatment on endothelial dysfunction by comparing the effect of QL to tha...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248414537705

    authors: Chen F,Wu JL,Fu GS,Mou Y,Hu SJ

    更新日期:2015-03-01 00:00:00

  • Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies.

    abstract::The primary effect of ischemia is reduced aerobic adenosine triphosphate (ATP) formation in mitochondria. This triggers accelerated glycolysis and reduced cell pH, Ca(2+) accumulation, K(+) efflux, adenosine formation, and the clinical signs of ischemia: chest pain and a shift in the ST segment. Traditional therapies ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/107424840400900104

    authors: Stanley WC

    更新日期:2004-09-01 00:00:00

  • Valsartan Promoting Atherosclerotic Plaque Stabilization by Upregulating Renalase: A Potential-Related Gene of Atherosclerosis.

    abstract:BACKGROUND:Renalase is a protein that can regulate sympathetic nerve activity by metabolizing catecholamines, while redundant catecholamines are thought to contribute to atherosclerosis (As). Catecholamine release can be facilitated by angiotensin (Ang) II by binding to Ang II type 1 (AT1) receptors. Valsartan, a speci...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248415575967

    authors: Zhou M,Ma C,Liu W,Liu H,Wang N,Kang Q,Li P

    更新日期:2015-09-01 00:00:00

  • Chronic Administration of Catestatin Improves Autonomic Function and Exerts Cardioprotective Effects in Myocardial Infarction Rats.

    abstract::Catestatin (CST), which is emerging as a novel cardiac modulator, can protect the heart against excessive sympathetic drive in hypertensive cardiomyopathy. The aim of this study is to investigate whether exogenous CST decreases excessive cardiac sympathetic drive and improves autonomic function and exerts cardioprotec...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248416628676

    authors: Wang D,Liu T,Shi S,Li R,Shan Y,Huang Y,Hu D,Huang C

    更新日期:2016-11-01 00:00:00

  • Roles of cyclooxygenase 2 in sevoflurane- and olprinone-induced early phase of preconditioning and postconditioning against myocardial infarction in rat hearts.

    abstract:PURPOSE:It is known that selective cyclooxygenase 2(COX-2) inhibitors increase mortality in patients with previous myocardial infarction, and it has been suggested that COX-2 plays an important role in cardioprotection against ischemia. The current study was carried out to determine whether COX-2 is involved in the mec...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248410380208

    authors: Tosaka S,Tosaka R,Matsumoto S,Maekawa T,Cho S,Sumikawa K

    更新日期:2011-03-01 00:00:00

  • Different Effects of Volatile and Nonvolatile Anesthetic Agents on Long-Term Survival in an Experimental Model of Hemorrhagic Shock.

    abstract:BACKGROUND:We investigated whether the cardioprotective, volatile gas anesthetic agent, isoflurane, could improve survival and organ function from hemorrhagic shock in an experimental rat model, compared to standard nonvolatile anesthetic agent ketamine/xylazine. METHODS:Sprague Dawley rats (both genders) were randomi...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248420919221

    authors: Dai W,Shi J,Carreno J,Kloner RA

    更新日期:2020-07-01 00:00:00

  • Diabetes, heart rate, and mortality.

    abstract::A large body of evidence indicates that a persistently high heart rate is associated with a significant risk for higher mortality and sudden death in individuals with a variety cardiovascular disorders, as well as in the general population. Heart rates elevated beyond a certain threshold have been found to be a risk f...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/107424840200700208

    authors: Singh N

    更新日期:2002-04-01 00:00:00

  • Omapatrilat induces profound renal vasodilation but does not affect coronary hemodynamics.

    abstract:BACKGROUND:Omapatrilat has potent enzymatic inhibitory effects on the angiotensin-converting enzyme and neutral endopeptidase. The prolonged effects of this inhibition on systemic and regional hemodynamics, cardiovascular mass, and hydroxyproline concentration in spontaneously hypertensive rats were studied. The contri...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840300800210

    authors: Varagic J,Susic D,Slama M,Frohlich ED

    更新日期:2003-06-01 00:00:00

  • Ventricular fibrillation induced by ischemia-reperfusion is not prevented by the NPY Y2 receptor antagonist BIIE0246.

    abstract::Neuropeptide Y is released together with norepinephrine from sympathetic nerve terminals during conditions of increased sympathetic activity. Neuropeptide Y is known to inhibit vagal activity, and accordingly, it might increase the risk for ventricular fibrillation during myocardial ischemia-reperfusion, with concomit...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248406292709

    authors: Ilebekk A,Eriksen M,Sevre K,Aspelin T,Björkman JA,Lyberg T,Nordlander M

    更新日期:2006-09-01 00:00:00

  • Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure.

    abstract:INTRODUCTION:Limited data exist comparing the efficacy and safety of bumetanide- or metolazone-based diuretic regimens to furosemide in acute heart failure (HF). Our purpose was to evaluate the comparative effect on urine output (UO) and renal function between these regimens. METHODS:A retrospective study of hospitali...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248413482755

    authors: Ng TM,Konopka E,Hyderi AF,Hshieh S,Tsuji Y,Kim BJ,Han SY,Phan DH,Jeng AI,Lou M,Elkayam U

    更新日期:2013-07-01 00:00:00

  • Effect of potassium-channel opener therapy on reperfused infarction in hypertrophied hearts: demonstration of preconditioning by using functional and contrast-enhanced magnetic resonance imaging.

    abstract::Effects of therapy with the potassium-channel opener and vasodilator nicorandil were studied in reperfused infarction of hypertrophied hearts by using magnetic resonance imaging (MRI), hemodynamic measurements, and histochemical staining. Aortic banding was performed on 22 Sprague-Dawley rats to induce left ventricula...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424840400900307

    authors: Schalla S,Higgins CB,Chujo M,Saeed M

    更新日期:2004-09-01 00:00:00

  • Astaxanthin reduces oxidative stress, but not aortic damage in atherosclerotic rabbits.

    abstract::We evaluated whether carotenoid astaxanthin (ASX) could prevent oxidative and atherosclerotic damage in rabbits. Rabbits received regular chow (control) or an atherogenic diet (1% cholesterol) alone or supplemented with 50, 100, and 500 mg% ASX for 60 days (n = 5-9 per group). The atherogenic diet increased the serum ...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248409350136

    authors: Augusti PR,Conterato GM,Somacal S,Sobieski R,Quatrin A,Maurer L,Rocha MP,Denardin IT,Emanuelli T

    更新日期:2009-12-01 00:00:00

  • The Novel Class III Antiarrhythmic Agent MS-551 Blocks the Cardiac Inward Rectifier With Greater Potency Than Sotalol or E-4031: Possible Relevance to Reverse Use Dependence.

    abstract::BACKGROUND: The tendency for the electrophysiologic effect of class III antiarrhythmic agents (action potential prolongation) to be diminished at faster heart rates represents a major drawback of this class of drug and is usually referred to as "reverse use dependence." A novel class III agent, MS-551, has recently be...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/107424849700200105

    authors: Nakaya Y,Martin DK,Campbell TJ

    更新日期:1997-01-01 00:00:00

  • Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension.

    abstract::Pulmonary arterial hypertension (PAH) is a progressive disease, which can be potentially fatal. The management of a complex disease like PAH requires a multidisciplinary approach from a team consisting of physicians, nurses, social workers, and pharmacists. Adherence to PAH-specific therapy is one of the key factors i...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章,评审

    doi:10.1177/1074248419877409

    authors: Narechania S,Torbic H,Tonelli AR

    更新日期:2020-03-01 00:00:00

  • Stable cystatin C serum levels confirm normal renal function in patients with dronedarone-associated increase in serum creatinine.

    abstract::Dronedarone is a new antiarrhythmic drug for patients with nonpermanent atrial fibrillation (AF). A relatively consistent finding in all trials studying dronedarone was a moderate but significant elevation of serum creatinine. Since dronedarone competes for the same organic cation transporter in the distal renal tubul...

    journal_title:Journal of cardiovascular pharmacology and therapeutics

    pub_type: 杂志文章

    doi:10.1177/1074248412453873

    authors: Duncker D,Oswald H,Gardiwal A,Lüsebrink U,König T,Schreyer H,Klein G

    更新日期:2013-03-01 00:00:00